Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

VIEWS: 91 PAGES: 141

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market Summary GBI Research, the leading business intelligence provider, has released its latest research “Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented. Scope The report covers - - Data and analysis on the sleep disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the sleep disorders therapeutics market from 2002 to 2010, with forecasts to 2017. - Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population. - Key drivers and restraints that have had a significant impact on the market. - The competitive landscape of the

More Info
									          Sleep Disorders Market to 2017 - Generic Substitution
              Coupled With a Weak Pipeline Will Negatively
                           Impact the Market
 Reference Code: GBIHC095MR                                                                                               Publication Date: April 2011


                                      The report contains four major indications under the sleep disorders market, namely, insomnia,
                                      restless leg syndrome, narcolepsy and sleep apnea. The overall sleep disorders market containing
                                      the four major indications mentioned was valued at $3.5 billion in 2010, and is expected to decline
                                      to approximately $3.4 billion by 2017.
                                      High Growth Rate and Increasing Necessity for CNS Drugs has Made the Sleep Disorder
                                      Market Attractive

    Sleep disorders                    Sleep Disorders Market, Revenue Forecasts ($bn), 2002–2017
    therapeutics market was
    growing at the rate of                                 4.0                                                       CAGR (2010-2017): -0.4%
    7.2% from 2002 and is
    valued to $3.5 billion in
                                                           3.5   CAGR (2002-2010): 7.2%
    2010. This rapid growth
    has made the market
    attractive.                                            3.0



                                                           2.5
                                           Revenue ($bn)




                                                           2.0



                                                           1.5



                                                           1.0



                                                           0.5



                                                           0.0
                                                                       2002                          2010                           2017


                                       Source: GBI Research



                                      The sleep disorders market has been a fast growing market, with insomnia considered to be the
                                      prime factor for chronic disability in the workforce. In 2010, the Sleep Disorders Market was worth
                                      $3.5 billion, which is forecast to decrease to $3.4 billion by 2017, with a rate of -0.4% between 2010
                                      and 2017. This is mainly affected by insomnia, which is a leading indication among all types of
                                      sleep disorders.
                                      The insomnia therapeutics market has been growing at a fast pace over the past few years, but is
                                      expected to decline with a rate of -3.8% from 2011 to 2017 due to high competition in the market,
                                      which will be a barrier for prospective entrants. This competition can be transmitted over other
                                      indications in the market such as restless leg syndrome, narcolepsy and sleep apnea. This can be
                                      carried out by practicing patient awareness about the diseases and types of treatments, while the
                                      other method is by increasing diagnosis.




Sleep Disorders Market to 2017 - Generic Substitution Coupled                                                          GBIHC095MR /Published APR 2011
With a Weak Pipeline Will Negatively Impact the Market
                                                                                                                                                   Page 1
                                                                                    © GBI Research. This is a licensed product and is not to be photocopied
                                      The Insomnia market will Decline Moderately Due to Patent Expirations
     Insomnia accounts for            The insomnia therapeutics market was a growing market during 2002-2009, and the growth was
     79% of sleep disorder            dominated by the US market. The growth rate is likely to decline from 2011 onwards due to the
     therapeutics market and          impact of patent expiry of key drugs. However, new branded drugs will minimize the impact of
     will decline due to patent       generic erosion to some extent. This impact will be seen due to patent expiries in the insomnia
     expiries with a rate of -        market, as it accounts for approximately 79% share of the global market. The global insomnia
     3.8% that will cause             therapeutics market is expected to decline at a CAGR of -3.8%, from $2.8 billion in 2010 to $2.1
     shrinkage of global sleep        billion in 2017. The major causes for decline in the market are patent expiries of major drugs and
     disorder market.                 weak profile of current pipeline molecules. The global insomnia therapeutics market in 2010 was
                                      worth $2.8 billion, which was primarily formed of three brands, namely Lunesta (eszopiclone), Paxil
                                      (paroxetine) and Ambien (zolpidem). The cost of therapy for branded products is in the range of
                                      $750 to $1,002 for duration of six months, as compared to those of generics which is between $10
                                      and $20 for the same duration. The most popular product for insomnia was Ambien (including
                                      generics and (Controlled Releases [CRs]), which demonstrates the large extent to which older
                                      generation products have been successful in terms of satisfying market demand. Ambien was
                                      approved for short term treatment of insomnia, while Ambien CR was approved for prescription for
                                      up to six months in 1991. The Average Selling Price (ASP) of products in the market is in the
                                      Restless Leg Syndrome, Narcolepsy and Sleep Apnea are Dominated by Late-Stage Pipeline
                                      Molecules that will Boost the Competition

     Restless leg syndrome,            Sleep Disorders Market, R&D Pipeline by Phase (%), 2004-2010
     narcolepsy and sleep
     apnea will support the                                                           NDA Filed         Discovery
     sleep disorder                                                                     8%                 7%     Preclinical phase
     therapeutics market with                                                                                            5%

     their strong pipeline
     molecules.                                                                                                             Phase I
                                                                                                                             10%



                                                                    Phase III
                                                                      30%




                                                                                                                 Phase II
                                                                                                                  40%

                                       Source: GBI Research’s Internal Database, Company Websites, Clinicaltrials.gov



                                      The restless leg syndrome, narcolepsy and sleep apnea pipeline portfolios have 12, five and 11
                                      molecules across the different developmental stages, respectively. The number of programs in the
                                      regulatory filing, Phase III and Phase II stages of development accounted for approximately 79% of
                                      the total number of pipeline programs. This indicates that the imminent launch of these drugs could
                                      increase the sleep disorder market value.
                                      The restless leg syndrome market has a strong pipeline that will support the growth of this market,
                                      thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical
                                      companies such as UCB Group, GlaxoSmithKline plc, axxonis Pharma AG, Ligand
                                      Pharmaceuticals Incorporated, National Institute of Neurological Disorders and Stroke, Kyowa
                                      Hakko Kirin Co., Ltd., Jazz Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Omeros Corporation
                                      and Manhattan Pharmaceuticals, Inc., are actively developing molecules for restless leg syndrome.
                                      The entry of pipeline molecules will boost the sleep disorder therapeutics market, thereby bringing
                                      about further rises in the sleep disorder therapeutics market in the coming years. Rapid entry of
                                      new players and highly active pipelines will intensify competition.




Sleep Disorders Market to 2017 - Generic Substitution Coupled                                                           GBIHC095MR /Published APR 2011
With a Weak Pipeline Will Negatively Impact the Market
                                                                                                                                                Page 2
                                                                                © GBI Research. This is a licensed product and is not to be photocopied
                                      1      Table of Contents
                                      1   Table of Contents ........................................................................................................................ 3
                                          1.1    List of Tables..................................................................................................................... 6
                                          1.2    List of Figures ................................................................................................................... 9
                                      2   Sleep Disorders Market: Introduction ........................................................................................ 11
                                          2.1    GBI Research Report Guidance ..................................................................................... 12
                                      3   Sleep Disorders Market to 2017: Market Overview ................................................................... 13
                                          3.1    Introduction ..................................................................................................................... 13
                                          3.2    Revenue Forecasts for the Sleep Disorder Therapeutics Market.................................... 14
                                             3.2.1    Revenue .................................................................................................................. 14
                                             3.2.2    Annual Cost of Treatment (ACT) ............................................................................. 15
                                             3.2.3    Treatment Usage Patterns ...................................................................................... 17
                                      4   Sleep Disorders Market to 2017: Geographical Landscape ...................................................... 23
                                          4.1    Revenue Analysis by Geography .................................................................................... 23
                                          4.2    The US ............................................................................................................................ 25
                                             4.2.1    Revenue .................................................................................................................. 25
                                             4.2.2    Annual Cost of Treatment........................................................................................ 26
                                             4.2.3    Treatment Usage Patterns ...................................................................................... 28
                                          4.3    Top Five Countries of Europe ......................................................................................... 35
                                             4.3.1    Revenue .................................................................................................................. 35
                                             4.3.2    Annual Cost of Treatment........................................................................................ 36
                                             4.3.3    Treatment Usage Patterns ...................................................................................... 37
                                          4.4    Japan .............................................................................................................................. 43
                                             4.4.1    Revenue .................................................................................................................. 43
                                             4.4.2    Annual Cost of Treatment........................................................................................ 44
                                             4.4.3    Treatment Usage Patterns ...................................................................................... 45
                                      5   Sleep Disorders Market: Therapeutic Landscape ...................................................................... 51
                                          5.1    Insomnia Therapeutics Market ........................................................................................ 51
                                             5.1.1    Introduction .............................................................................................................. 51
                                             5.1.2    Revenue .................................................................................................................. 52
                                             5.1.3    Annual Cost of Treatment........................................................................................ 53
                                             5.1.4    Treatment Usage Patterns ...................................................................................... 54
                                             5.1.5    Drivers and Barriers for the Insomnia Therapeutics Market .................................... 60
                                          5.2    Restless Leg Syndrome Therapeutics Market ................................................................ 61
                                             5.2.1    Introduction .............................................................................................................. 61
                                             5.2.2    Revenue .................................................................................................................. 62
                                             5.2.3    Annual Cost of Treatment........................................................................................ 63
                                             5.2.4    Treatment Usage Patterns ...................................................................................... 64
                                             5.2.5    Drivers and Barriers for the Restless Leg Syndrome Therapeutics Market ............. 70
                                          5.3    Narcolepsy Therapeutics Market .................................................................................... 71
                                             5.3.1    Introduction .............................................................................................................. 71
                                             5.3.2    Revenue .................................................................................................................. 72
                                             5.3.3    Annual Cost of Treatment........................................................................................ 73
                                             5.3.4    Treatment Usage Patterns ...................................................................................... 74
                                             5.3.5    Drivers and Barriers for the Narcolepsy Therapeutics Market ................................. 80
                                          5.4    Sleep Apnea Therapeutics Market .................................................................................. 81
                                             5.4.1    Introduction .............................................................................................................. 81
                                             5.4.2    Revenue .................................................................................................................. 82
                                             5.4.3    Annual Cost of Treatment........................................................................................ 83
                                             5.4.4    Treatment Usage Patterns ...................................................................................... 84
                                             5.4.5    Drivers and Barriers for the Sleep Apnea Therapeutics Market .............................. 90
                                      6   Sleep Disorders Market to 2017: Pipeline Analysis ................................................................... 92
                                          6.1    Introduction ..................................................................................................................... 92
                                          6.2    Research and Development Pipeline – Sleep Disorders ................................................ 93


Sleep Disorders Market to 2017 - Generic Substitution Coupled                                                                          GBIHC095MR /Published APR 2011
With a Weak Pipeline Will Negatively Impact the Market
                                                                                                                                                                              Page 3
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                        6.3    Insomnia – Pipeline Analysis .......................................................................................... 93
                                           6.3.1   Introduction .............................................................................................................. 93
                                           6.3.2   Insomnia Therapeutics Market – Pipeline Assessment by Clinical Phase of
                                                   Development ........................................................................................................... 94
                                           6.3.3   Filed Molecules........................................................................................................ 95
                                           6.3.4   Phase III .................................................................................................................. 95
                                           6.3.5   Phase II ................................................................................................................... 96
                                           6.3.6   Phase I .................................................................................................................... 97
                                           6.3.7   Preclinical Phase ..................................................................................................... 97
                                           6.3.8   Discovery Phase...................................................................................................... 97
                                        6.4    Restless Leg Syndrome Therapeutics Market: Pipeline Analysis ................................... 98
                                           6.4.1   Introduction .............................................................................................................. 98
                                           6.4.2   Narcolepsy Therapeutics Market – Pipeline Assessment by Clinical Phase of
                                                   Development ........................................................................................................... 99
                                        6.5    Narcolepsy Therapeutics Market – Pipeline Analysis ................................................... 100
                                           6.5.1   Introduction ............................................................................................................ 100
                                           6.5.2   Narcolepsy Therapeutics Market – Pipeline Assessment by Clinical Phase of
                                                   Development ......................................................................................................... 101
                                        6.6    Sleep Apnea Therapeutics Market – Pipeline Analysis ................................................. 102
                                           6.6.1   Introduction ............................................................................................................ 102
                                           6.6.2   Sleep Apnea Therapeutics Market – Pipeline Assessment by Clinical Phase of
                                                   Development ......................................................................................................... 103
                                      7 Sleep Disorder Market to 2016: Competitive Landscape......................................................... 104
                                        7.1    Overview ....................................................................................................................... 104
                                        7.2    Competitive Profiling ..................................................................................................... 104
                                           7.2.1   Sanofi-Aventis ....................................................................................................... 104
                                           7.2.2   King Pharmaceuticals, Inc. .................................................................................... 107
                                           7.2.3   Questcor Pharmaceuticals, Inc. ............................................................................. 108
                                           7.2.4   Novartis ................................................................................................................. 109
                                           7.2.5   GlaxoSmithKline plc .............................................................................................. 111
                                           7.2.6   Pfizer ..................................................................................................................... 113
                                           7.2.7   Boehringer Ingelheim ............................................................................................ 115
                                           7.2.8   Cephalon Pharmaceuticals .................................................................................... 119
                                           7.2.9   Schwarz Pharma ................................................................................................... 121
                                           7.2.10 Mylan Pharma ....................................................................................................... 125
                                      8 Sleep Disorders Market to 2017: M&A Landscape .................................................................. 127
                                        8.1    Sleep Disorders Market ................................................................................................ 127
                                           8.1.1   Overview: Deals by Type....................................................................................... 127
                                           8.1.2   Deals by Year ........................................................................................................ 128
                                        8.2    Mergers and Acquisitions .............................................................................................. 128
                                           8.2.1   Overview ............................................................................................................... 128
                                           8.2.2   Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo .. 128
                                           8.2.3   Eli Lilly Acquires Hypnion ...................................................................................... 129
                                           8.2.4   Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical .......... 129
                                           8.2.5   Sciele Pharma Acquires Alliant Pharmaceuticals .................................................. 130
                                           8.2.6   Jazz Pharmaceuticals Acquires Orphan Medical................................................... 130
                                           8.2.7   Paul Royalty Acquires US Royalty Rights of Estorra from Aventis ........................ 130
                                        8.3    Licensing Agreements .................................................................................................. 132
                                           8.3.1   GlaxoSmithKline (GSK) and Actelion Pharmaceuticals ......................................... 132
                                           8.3.2   Purdue Pharma Enters into License Agreement with Transcept Pharmaceuticals 132
                                           8.3.3   Neurocrine Biosciences Enters into Licensing Agreement with Dainippon Sumitomo
                                                   Pharma .................................................................................................................. 133
                                           8.3.4   Eli Lilly Enters into Licensing Agreement with Merck............................................. 133
                                           8.3.5   ECR Pharmaceuticals Enters into License Agreement with NovaDel Pharma ...... 133
                                           8.3.6   Vanda Enters into Licensing Agreement with Bristol-Myers Squibb ...................... 134


Sleep Disorders Market to 2017 - Generic Substitution Coupled                                                                       GBIHC095MR /Published APR 2011
With a Weak Pipeline Will Negatively Impact the Market
                                                                                                                                                                         Page 4
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                          8.4    Co-Development Strategies .......................................................................................... 135
                                      9   Sleep Disorders Market: Appendix .......................................................................................... 136
                                          9.1    Market Definition ........................................................................................................... 136
                                          9.2    Abbreviations ................................................................................................................ 136
                                          9.3    Research Methodology ................................................................................................. 137
                                             9.3.1    Coverage ............................................................................................................... 137
                                             9.3.2    Secondary Research ............................................................................................. 137
                                             9.3.3    Forecasting ............................................................................................................ 138
                                             9.3.4    Primary Research .................................................................................................. 140
                                             9.3.5    Expert Panels ........................................................................................................ 140
                                          9.4    Contact Us .................................................................................................................... 140
                                          9.5    Disclaimer ..................................................................................................................... 141
                                          9.6    Sources ......................................................................................................................... 141




Sleep Disorders Market to 2017 - Generic Substitution Coupled                                                                         GBIHC095MR /Published APR 2011
With a Weak Pipeline Will Negatively Impact the Market
                                                                                                                                                                            Page 5
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                      1.1    List of Tables
                                      Table 1:    Sleep Disorders Market, Global, Revenue ($bn), 2002-2010......................................... 14
                                      Table 2:    Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017 ........................ 14
                                      Table 3:    Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2002-2010 .................. 16
                                      Table 4:    Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2010-2017 .................. 16
                                      Table 5:    Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2010 ...... 17
                                      Table 6:    Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2010-2017 ...... 18
                                      Table 7:    Sleep Disorders Market, Global, Diseased Population (millions), 2002–2010 ............... 19
                                      Table 8:    Sleep Dis orders Market, Global, Diseased Population (millions), 2010–2017 .............. 19
                                      Table 9:    Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002–2010 20
                                      Table 10:   Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2010–2017 20
                                      Table 11:   Sleep Disorders Market, Global, Diagnosed Population (million), 2002–2010 ............... 21
                                      Table 12:   Sleep Disorders Market, Global, Diagnosed Population (million), 2010–2017 ............... 21
                                      Table 13:   Sleep Disorders Market, Global, Prescription Population (million), 2002–2010 ............. 22
                                      Table 14:   Sleep Disorders Market, Global, Prescription Population (million), 2010–2017 ............. 22
                                      Table 15:   Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 .. 24
                                      Table 16:   Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 .. 24
                                      Table 17:   Sleep Disorders Market, the US, Revenue ($bn), 2002-2010 ........................................ 25
                                      Table 18:   Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2010-2017 ....................... 25
                                      Table 19:   Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2010.................. 27
                                      Table 20:   Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2010-2017.................. 27
                                      Table 21:   Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2010...... 28
                                      Table 22:   Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2010-2017...... 29
                                      Table 23:   Sleep Disorders Market, the US, Diseased Population (millions), 2002–2010 ............... 30
                                      Table 24:   Sleep Disorders Market, the US, Diseased Population (millions), 2010–2017 ............... 30
                                      Table 25:   Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002–2010 32
                                      Table 26:   Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2010–2017 32
                                      Table 27:   Sleep Disorders Market, the US, Diagnosed Population (millions), 2002–2010............. 33
                                      Table 28:   Sleep Disorders Market, the US, Diagnosed Population (millions), 2010–2017............. 33
                                      Table 29:   Sleep Disorders Market, the US, Prescription Population (millions), 2002–2010 ........... 34
                                      Table 30:   Sleep Disorders Market, the US, Prescription Population (millions), 2010–2017 ........... 34
                                      Table 31:   Sleep Disorders Market, Top Five EU Countries, Revenue ($bn), 2002-2010 ............... 35
                                      Table 32:   Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2017
                                                  ....................................................................................................................................... 35
                                      Table 33:   Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($),
                                                  2002-2010 ...................................................................................................................... 36
                                      Table 34:   Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($),
                                                  2010-2017 ...................................................................................................................... 36
                                      Table 35:   Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns
                                                  (millions), 2002-2010...................................................................................................... 37
                                      Table 36:   Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns
                                                  (millions), 2010-2017...................................................................................................... 38
                                      Table 37:   Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions),
                                                  2002–2010 ..................................................................................................................... 39
                                      Table 38:   Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions),
                                                  2010–2017 ..................................................................................................................... 39
                                      Table 39:   Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population
                                                  (millions), 2002–2010 ..................................................................................................... 40
                                      Table 40:   Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population
                                                  (millions), 2010–2017 ..................................................................................................... 40
                                      Table 41:   Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions),
                                                  2002–2010 ..................................................................................................................... 41
                                      Table 42:   Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions),
                                                  2010–2017 ..................................................................................................................... 41
                                      Table 43:   Sleep Disorders Market, Top Five Countries in Europe, Prescription Population
                                                  (millions), 2002–2010 ..................................................................................................... 42
                                      Table 44:   Sleep Disorders Market, Top Five Countries in Europe, Prescription Population
                                                  (millions), 2010–2017 ..................................................................................................... 42
                                      Table 45:   Sleep Disorders Market, Japan, Revenue ($bn), 2002-2010 ......................................... 43
                                      Table 46:   Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2010-2017 .......................... 43
                                      Table 47:   Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2010 ................... 44
                                      Table 48:   Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2010-2017 ................... 44

Sleep Disorders Market to 2017 - Generic Substitution Coupled                                                                            GBIHC095MR /Published APR 2011
With a Weak Pipeline Will Negatively Impact the Market
                                                                                                                                                                                 Page 6
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      Table 49:   Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2010 ....... 45
                                      Table 50:   Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2010-2017 ....... 46
                                      Table 51:   Sleep Disorders Market, Japan, Diseased Population (millions), 2002–2010 ................ 47
                                      Table 52:   Sleep Disorders Market, Japan, Diseased Population (millions), 2010–2017 ................ 47
                                      Table 53:   Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002–2010 . 48
                                      Table 54:   Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2010–2017 . 48
                                      Table 55:   Sleep Disorders Market, Japan, Diagnosed Population (millions), 2002–2010 .............. 49
                                      Table 56:   Sleep Disorders Market, Japan, Diagnosed Population (millions), 2010–2017 .............. 49
                                      Table 57:   Sleep Disorders Market, Japan, Prescription Population (millions), 2002–2010 ............ 50
                                      Table 58:   Sleep Disorders Market, Japan, Prescription Population (millions), 2010–2017 ............ 50
                                      Table 59:   Insomnia Therapeutics Market, Global, Revenue ($bn), 2002-2010 .............................. 52
                                      Table 60:   Insomnia Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 ............... 52
                                      Table 61:   Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010....... 53
                                      Table 62:   Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017....... 53
                                      Table 63:   Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
                                                  ....................................................................................................................................... 54
                                      Table 64:   Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
                                                  ....................................................................................................................................... 55
                                      Table 65:   Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2010..... 56
                                      Table 66:   Insomnia Therapeutics Market, Global, Diseased Population (millions), 2010-2017..... 56
                                      Table 67:   Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-
                                                  2010 ............................................................................................................................... 57
                                      Table 68:   Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-
                                                  2017 ............................................................................................................................... 57
                                      Table 69:   Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 .. 58
                                      Table 70:   Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 .. 58
                                      Table 71:   Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2010.. 59
                                      Table 72:   Insomnia Therapeutics Market, Global, Prescription Population (millions), 2010-2017.. 59
                                      Table 73:   Restless Leg Syndrome Therapeutics Market, Global, Revenue ($bn), 2002-2010 ..... 62
                                      Table 74:   Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecast ($bn), 2010-
                                                  2017 ............................................................................................................................... 62
                                      Table 75:   Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                  2002-2010 ...................................................................................................................... 63
                                      Table 76:   Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment($),
                                                  2010-2017 ...................................................................................................................... 63
                                      Table 77:   Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns
                                                  (millions), 2002-2010...................................................................................................... 64
                                      Table 78:   Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns
                                                  (millions), 2010-2017...................................................................................................... 65
                                      Table 79:   Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions),
                                                  2002-2010 ...................................................................................................................... 66
                                      Table 80:   Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions),
                                                  2010-2017 ...................................................................................................................... 66
                                      Table 81:   Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population
                                                  (millions), 2002-2010...................................................................................................... 67
                                      Table 82:   Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population
                                                  (millions), 2010-2017...................................................................................................... 67
                                      Table 83:   Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions),
                                                  2002-2010 ...................................................................................................................... 68
                                      Table 84:   Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions),
                                                  2010-2017 ...................................................................................................................... 68
                                      Table 85:   Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions),
                                                  2002-2010 ...................................................................................................................... 69
                                      Table 86:   Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions),
                                                  2010-2017 ...................................................................................................................... 69
                                      Table 87:   Narcolepsy Therapeutics Market, Global, Revenue ($m), 2002-2010............................ 72
                                      Table 88:   Narcolepsy Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017 ............. 72
                                      Table 89:   Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 ... 73
                                      Table 90:   Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 ... 73
                                      Table 91:   Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-
                                                  2010 ............................................................................................................................... 74
                                      Table 92:   Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-
                                                  2017 .....................
								
To top